Your browser doesn't support javascript.
loading
Excess pancreatic elastase alters acinar-ß cell communication by impairing the mechano-signaling and the PAR2 pathways.
Basile, Giorgio; Vetere, Amedeo; Hu, Jiang; Ijaduola, Oluwaseun; Zhang, Yi; Liu, Ka-Cheuk; Eltony, Amira M; De Jesus, Dario F; Fukuda, Kazuki; Doherty, Grace; Leech, Colin A; Chepurny, Oleg G; Holz, George G; Yun, Seok-Hyun; Andersson, Olov; Choudhary, Amit; Wagner, Bridget K; Kulkarni, Rohit N.
Afiliação
  • Basile G; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Vetere A; Chemical Biology and Therapeutics Science Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Hu J; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Ijaduola O; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Zhang Y; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Liu KC; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm 171 77, Sweden.
  • Eltony AM; Harvard Medical School and Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.
  • De Jesus DF; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Fukuda K; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Doherty G; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA.
  • Leech CA; Department of Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY 13210, USA.
  • Chepurny OG; Department of Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY 13210, USA.
  • Holz GG; Department of Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY 13210, USA; Department of Pharmacology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY 13210, USA.
  • Yun SH; Harvard Medical School and Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.
  • Andersson O; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm 171 77, Sweden.
  • Choudhary A; Chemical Biology and Therapeutics Science Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Wagner BK; Chemical Biology and Therapeutics Science Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Kulkarni RN; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA 02215, USA. Electronic address: rohit.kulkarni@joslin.harvard.edu.
Cell Metab ; 35(7): 1242-1260.e9, 2023 07 11.
Article em En | MEDLINE | ID: mdl-37339634
ABSTRACT
Type 1 (T1D) or type 2 diabetes (T2D) are caused by a deficit of functional insulin-producing ß cells. Thus, the identification of ß cell trophic agents could allow the development of therapeutic strategies to counteract diabetes. The discovery of SerpinB1, an elastase inhibitor that promotes human ß cell growth, prompted us to hypothesize that pancreatic elastase (PE) regulates ß cell viability. Here, we report that PE is up-regulated in acinar cells and in islets from T2D patients, and negatively impacts ß cell viability. Using high-throughput screening assays, we identified telaprevir as a potent PE inhibitor that can increase human and rodent ß cell viability in vitro and in vivo and improve glucose tolerance in insulin-resistant mice. Phospho-antibody microarrays and single-cell RNA sequencing analysis identified PAR2 and mechano-signaling pathways as potential mediators of PE. Taken together, our work highlights PE as a potential regulator of acinar-ß cell crosstalk that acts to limit ß cell viability, leading to T2D.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina Idioma: En Ano de publicação: 2023 Tipo de documento: Article